[go: up one dir, main page]

MX2016008662A - Composicion farmaceutica que no contiene antioxidantes y metodo de preparacion de la misma. - Google Patents

Composicion farmaceutica que no contiene antioxidantes y metodo de preparacion de la misma.

Info

Publication number
MX2016008662A
MX2016008662A MX2016008662A MX2016008662A MX2016008662A MX 2016008662 A MX2016008662 A MX 2016008662A MX 2016008662 A MX2016008662 A MX 2016008662A MX 2016008662 A MX2016008662 A MX 2016008662A MX 2016008662 A MX2016008662 A MX 2016008662A
Authority
MX
Mexico
Prior art keywords
preparation
pharmaceutical composition
method therefor
composition
containing antioxidant
Prior art date
Application number
MX2016008662A
Other languages
English (en)
Other versions
MX366953B (es
Inventor
Woong CHO Joong-
Hae Kim Gyeong-
Hyo SEO Min-
Won Lee Sa-
Original Assignee
Samyang Biopharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samyang Biopharmaceuticals filed Critical Samyang Biopharmaceuticals
Publication of MX2016008662A publication Critical patent/MX2016008662A/es
Publication of MX366953B publication Critical patent/MX366953B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporciona una composición que contiene un fármaco tal como pemetrexed cuya degradación puede ocurrir fácilmente por oxidación y que tiene alta estabilidad al no usar antioxidante y eliminar el oxígeno de un proceso para preparar una composición; y un método para preparar la composición. El método de preparación tiene alta facilidad de preparación congelando y desgasificando la composición en un contenedor sellado y puede proporcionar la composición que tiene una elevada estabilidad innovadora de un fármaco que es inestable en oxidación.
MX2016008662A 2013-12-30 2014-12-26 Composición farmacéutica que no contiene antioxidantes y método de preparación de la misma. MX366953B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020130167677A KR101703980B1 (ko) 2013-12-30 2013-12-30 항산화제를 함유하지 않는 약학 조성물 및 그의 제조방법
PCT/KR2014/012886 WO2015102315A1 (ko) 2013-12-30 2014-12-26 항산화제를 함유하지 않는 약학 조성물 및 그의 제조방법

Publications (2)

Publication Number Publication Date
MX2016008662A true MX2016008662A (es) 2017-02-02
MX366953B MX366953B (es) 2019-07-31

Family

ID=53493608

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008662A MX366953B (es) 2013-12-30 2014-12-26 Composición farmacéutica que no contiene antioxidantes y método de preparación de la misma.

Country Status (8)

Country Link
US (1) US10300063B2 (es)
EP (1) EP3090746B1 (es)
JP (1) JP6505114B2 (es)
KR (1) KR101703980B1 (es)
CN (1) CN105979949B (es)
BR (1) BR112016015190B1 (es)
MX (1) MX366953B (es)
WO (1) WO2015102315A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101919436B1 (ko) 2015-05-28 2018-11-16 주식회사 삼양바이오팜 안정화된 약학 조성물 및 그의 제조방법
US20170239250A1 (en) 2016-02-19 2017-08-24 Eagle Pharmaceuticals, Inc. Pemetrexed formulations
JP2019505561A (ja) * 2016-02-19 2019-02-28 イーグル ファーマシューティカルズ， インコーポレイテッド ペメトレキセド製剤
US10793573B2 (en) 2017-08-31 2020-10-06 Duquesne University Of The Holy Spirit First-in-class of SHMT2 and MTHFD2 inhibitors as antitumor agents
JP7282065B2 (ja) * 2020-10-05 2023-05-26 イーグル ファーマシューティカルズ， インコーポレイテッド ペメトレキセド製剤
KR102886965B1 (ko) * 2022-02-28 2025-11-17 한국유나이티드제약 주식회사 향상된 용해도를 가지는 닥티노마이신 함유 약학조성물의 제조방법
CN117693334B (zh) * 2022-06-09 2025-11-18 上海云晟研新生物科技有限公司 培美曲塞二钠液体组合物、其制备方法及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58463B2 (ja) * 1979-02-05 1983-01-06 日本原子力研究所 イオン交換膜の新規製造方法
TR200401436T4 (tr) 2000-02-04 2004-07-21 Eli Lilly And Company Monotiyogliserol, L-sistem veya tiyoglikolik asitle birlikte pemetrexed içeren farmasötik bileşim
US6686365B2 (en) * 2000-02-04 2004-02-03 Eli Lilly And Company Pharmaceutical composition
JP4815586B2 (ja) 2005-08-12 2011-11-16 国立大学法人 筑波大学 Ａｕ２５クラスターの選択的大量合成方法
US20070077303A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for providing oxidatively stable ophthalmic compositions
FR2894154B1 (fr) * 2005-12-06 2008-03-14 Pharmatop Scr Nouveau procede de stabilisation de substances minerales ou organiques sensibles a l'oxydation.
US8629152B2 (en) 2006-08-14 2014-01-14 Sicor, Inc. Processes for the preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid
EP2072518A1 (en) * 2007-12-23 2009-06-24 Sun Pharma Advanced Research Company Limited Stable Amorphous Form of Pemextred Disodium
WO2010030598A2 (en) * 2008-09-11 2010-03-18 Dr. Reddy's Laboratories Limited Pharmaceutical formulations comprising pemetrexed
CN101411710B (zh) * 2008-11-25 2011-06-15 江苏奥赛康药业有限公司 培美曲塞二钠冻干粉针剂及其制备方法
EP2598148A4 (en) * 2010-07-28 2014-05-28 Eagle Pharmaceuticals Inc PHARMACEUTICAL COMPOSITIONS WITH PEMETREXED WITH EXTENDED STORAGE STABILITY
KR101069128B1 (ko) * 2011-03-10 2011-09-30 건일제약 주식회사 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법
WO2013144814A1 (en) 2012-03-27 2013-10-03 Fresenius Kabi Oncology Ltd. Stable ready-to-use pharmaceutical composition of pemetrexed
KR20130122065A (ko) * 2012-04-30 2013-11-07 씨제이제일제당 (주) 페메트렉시드를 함유하는 안정화된 주사용 액상 제제
WO2014060962A1 (en) * 2012-10-17 2014-04-24 Shilpa Medicare Limited Pemetrexed dipotassium formulations
KR101260636B1 (ko) 2012-11-29 2013-05-13 씨제이제일제당 (주) 안정화된 페메트렉시드 제제
CN103432086B (zh) * 2013-08-28 2015-07-22 南京正大天晴制药有限公司 一种注射用培美曲塞二钠冻干粉针剂及其制备方法

Also Published As

Publication number Publication date
CN105979949B (zh) 2019-03-08
BR112016015190A8 (pt) 2023-04-25
EP3090746A4 (en) 2017-08-09
BR112016015190A2 (pt) 2017-08-08
EP3090746B1 (en) 2019-06-19
JP6505114B2 (ja) 2019-04-24
KR20150078376A (ko) 2015-07-08
US20160317539A1 (en) 2016-11-03
WO2015102315A1 (ko) 2015-07-09
EP3090746A1 (en) 2016-11-09
CN105979949A (zh) 2016-09-28
KR101703980B1 (ko) 2017-02-08
JP2017506213A (ja) 2017-03-02
US10300063B2 (en) 2019-05-28
BR112016015190B1 (pt) 2023-05-02
MX366953B (es) 2019-07-31

Similar Documents

Publication Publication Date Title
MX2016008662A (es) Composicion farmaceutica que no contiene antioxidantes y metodo de preparacion de la misma.
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
MY190561A (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
JO3275B1 (ar) مشتقات بيرول جديدة وطريقة لتحضيرها وتركيبات صيدلانية التي تحتوي عليها
WO2012121523A3 (en) Process for preparing pharmaceutical formulation in form of antioxidant-free solution for injection containing pemetrexed or its salt
MX351980B (es) Método y dispositivo para la disolucion rápida de composición sólida de proteinas solidas.
ZA201600415B (en) Novel derivatives of indole and pyrrole, method for the production thereof and pharmaceutical compositions containing same
AR100618A1 (es) Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
MX347882B (es) Procedimiento mejorado para preparar (3e, 7e)-homofarnesol.
MX2016008369A (es) Composicion farmaceutica que incluye palonosetron.
MX2016015464A (es) Composicion farmaceutica oral de isotretinoina.
PH12017501828A1 (en) Stabilized pharmaceutical composition and method for preparing same
EP3263573A4 (en) Crystal of imidazo-oxazine, pharmaceutical composition containing said crystal, and method for producing said crystal
TN2012000436A1 (en) Agomelatine hydrobromide hydrate and preparation thereof
MX2015003034A (es) Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso.
PH12016502544B1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
RU2012151073A (ru) Способ стабилизации раствора дигидрокверцетина
WO2015097717A3 (en) AN IMPROVED PROCESS FOR THE PREPARATION OF β-CAROTENE
BR112016016690A2 (pt) processo para a reconstituição de uma forma sólida de uma composição farmacêutica
IN2014MU03425A (es)
WO2017093866A3 (en) An improved process for the preparation of indigo carmine
EP3240575A4 (en) Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib
MX2016009458A (es) Solucion alcoholica estable de alprostadilo.
MX2015017198A (es) Matriz.
IN2013MU03508A (es)

Legal Events

Date Code Title Description
FG Grant or registration